维普期刊资源整合服务平台（V6.5）

维普中文期刊产品整合服务

17篇 您的检索式：作者名="ZEGELS B"

选中清除导出查看参考文献查看引证文献引用追踪共1页首页上一页第1页下一页末页 /1 跳转

		题名	作者	年代	出处	被引量
	1	A 2-year phase II study with 1-year of follow-up of risedronate(NE-58O95)in postmenopausal osteoporosis显示文摘	Clemmesen B Ravn P Zegels B	1997	Osteoporosis Int1997，7，：	1
	2	A 2-year phase II study with 1-year of follow-up of risedronate(NE-58095) in postmenopausal osteoporosis显示文摘	Clemmesen B Ravn P Zegels B	1997	Osteoporosis Int1997，7，5：	1
	3	A 2-year phase H study with 1-year of follow-up of risedronate(NE-58095)in postm- enopausal osteoporO6is显示文摘	Clemmesen B Ravn P Zegels B	1997	Osteoporosis Int1997，7，：	1
	4	Reduction in PINP,a marker of bone metabolism,with raloxifene treatment and its relationship with vertebral fracture risk显示文摘	RECINSTER J Y SARKAR S ZEGELS B	2004	Bone2004，34，：	1
	5	A 2-year phase ]l study with 1-year of follow-up of risedmnate (NE-58095) in postmenopausal osteoporosis 显示文摘	Clemmesen B Ravn P Zegels B	1997	Osteoporosis Int1997，7，5：	1
	6	Symptom and structure modifying properties of chondroitin sulfate in osteoarthritis 显示文摘	Reginster JY Heraud F Zegels B	2007	Mini Rev Med Chem2007，7，10：	1
	7	A 2-year phase II study with 1 - year of follow-up of risedronate ( NE - 58095 ) in postmenopausal os- teoporosis显示文摘	Clemmesen B Ravn P Zegels B	1997	Osteoporos Int1997，7，：	1
	8	A 2-year phaseⅡstudy with 1-year of follow-up of risedronate(NE-58095)in postmenopausal osteopo-rosis显示文摘	Clemmesen B Ravn P Zegels B	1997	Osteoporos Int1997，7，7：	1
	9	Reduction in PINP,a marker of bone metabolism,with raloxifene treatment and its relationship with vertebral fracture risk显示文摘	REGINSTER J Y SARKAR S ZEGELS B		0，，02：	1
	10	Development and assessment of the osteoporosis index of risk(OSIRIS) to facilitate selection of women for bone densitometry显示文摘	Sedrine WB Chevallier T Zegels B	2002	Gynecol Endocrinol2002，16，3：	1
	11	Development and assessment of the osteoporosis index of risk (OSIRIS) to facilitate selection of women for bone densitometry显示文摘	Sedrine W B Chevallier T Zegels B	2002	Gynecol Endocrinol2002，16，3：	1
	12	Development and assessment of the Osteoporosis Index of Risk (OSIRIS) to faeilitate selection of women for bone densitometry显示文摘	Sedrine WB Chevallier T Zegels B	2002	Gynecol Endocrinol2002，16，3：	1
	13	Reduction in PINP, a marker of bone metabolism, with raloxifene treatment and its relationship with vertebral fractuer risk显示文摘	REGINSTER J Y SARKAR S ZEGELS B	2004	Bone2004，34，：	1
	14	Development and assessment of the Osteoporosis Index of Risk (OSIRIS) to facilitate selection of women for bone densitometry显示文摘	Sedrine WB Chevallier T Zegels B	2002	Gynecol Endoorinol2002，16，3：	1
	15	Limited clinical utility of a self-evaluating risk assessment scale for postmenopausal osteoporosis:lack of predictive value of lifestyle-related factors显示文摘	Goemaere S Zegels B Toye K	1999	Calcif Tissue Int1999，65，：	1
	16	Development and assessment of the Osteoporosis lndex of Risk (OSIRIS) to facilitate selection of women for bone densitometry 显示文摘	Sedrine WB Chevallier T Zegels B	2002	Gynecol Endocr2002，16，3：	1
	17	A 2-year phase II study with 1-year of follow-up of risedronate(NE-58O95)in postmenopausal osteoporosis显示文摘	Clemmesen B Ravn P Zegels B	1997	Osteoporosis Int1997，7，：	1

返回顶部每页显示：

共1页首页上一页第1页下一页末页 /1 跳转

goolge学术搜索-维普

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1　渝公网安备 50019002500403号　违法和不良信息举报中心

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费